retinal-imaging
(5)
Character Biosciences
Character Biosciences is a precision medicine company developing targeted therapies for progressive polygenic diseases, starting in ophthalmology with age-related macular degeneration (AMD). By pairing human genetics with longitudinal clinical and retinal imaging data from thousands of consented patients - and layering AI-enabled biomarker analysis on top - Character reclassifies broad diagnoses into genetically defined subtypes so it can design drugs that target the root drivers of disease progression. Its lead programs, CTX114 (a complement inhibitor for geographic atrophy) and CTX203 (a lipid regulator to prevent progression to advanced AMD), are advancing toward the clinic on the strength of a Series B that grew past $110 million.
Digital Diagnostics
Digital Diagnostics is a Coralville, Iowa healthcare AI company that builds autonomous - not assistive - diagnostic systems that make a clinical decision without a physician reviewing the result. Its flagship product, LumineticsCore (formerly IDx-DR), was the first medical device of any kind to receive FDA authorization to make an autonomous diagnosis: it screens for diabetic retinopathy from retinal images at the point of care in primary care offices, no eye specialist required. Founded in 2010 by retina specialist and computer engineer Dr. Michael Abramoff, the company has raised more than $130 million to expand autonomous AI into new disease areas.
JuneBrain Inc.
JuneBrain Inc. is a Baltimore medtech startup building a wearable, AI-powered eye-scanning system that brings optical coherence tomography (OCT) out of the eye clinic and into neurology, primary care, and the home. Its flagship Neuro-i SS-OCT captures high-resolution retinal images without a technician, and its AI software turns those images into quantitative biomarkers clinicians can use to monitor diseases like multiple sclerosis, Alzheimer's, and Parkinson's between visits. Founded in 2017 by neuroscientist Samantha Scott after her own diagnosis with a neuromuscular disorder, the company is a WBENC-certified women-owned business on track for FDA submission in 2026.
identifeye HEALTH
identifeye HEALTH (formerly Tesseract Health) builds an AI-powered retinal imaging platform that turns a quick eye scan in a primary-care clinic into a window onto whole-body health, helping clinicians screen for diabetic retinopathy, glaucoma and macular degeneration without dilation or specialty equipment.
Intalight
Intalight is a US-based ophthalmic imaging company (the international brand of SVision Imaging / 视微影像, Luoyang, China) that builds high-speed swept-source OCT and OCT-angiography systems. Its flagship DREAM OCT platform images the whole eye in a single ultra-widefield scan, combining deep retinal penetration, anterior-segment imaging, biometry, and AI-driven segmentation for clinicians and researchers worldwide.